CEO, COB, 10%
Phillip Frost, M.D.
Director and 10% Owner, Cocrystal Pharma, Inc. (NASDAQ: COCP)
Phillip Frost, M.D., is a seasoned physician and biotechnology executive with decades of leadership in the pharmaceutical industry. He currently serves as Chairman and Chief Executive Officer of OPKO Health, Inc. (NYSE: OPK), a position he has held since March 2007. Previously, Dr. Frost was Chairman of the Board of Teva Pharmaceuticals (NYSE: TEVA) and led IVAX Corporation as Chairman and CEO from 1987 until its acquisition by Teva in January 2006. Earlier in his career, he chaired Key Pharmaceuticals from 1972 to 1986, overseeing its growth and sale to Schering-Plough. A co-founder of Cocrystal Pharma, Inc., Dr. Frost brings extensive expertise in pharmaceutical development, commercialization, and strategic investments.
At Cocrystal Pharma, Dr. Frost serves as a Director and 10% Owner, actively participating on the Audit, Compensation, and Nominating and Corporate Governance Committees. He has demonstrated strong commitment through recent insider transactions, including the acquisition of 20,000 shares on November 25, 2025, at an average price of $0.9406 via Frost Gamma Investments Trust (for which he is trustee), and an additional 4,000 shares on November 26, 2025, totaling approximately $3,975. These bring his indirect beneficial ownership to over 1.7 million shares through the trust and 27,100 shares directly (including restricted stock units). Dr. Frost also participated in a $1.03 million private placement in October 2025, underscoring his alignment with the company's antiviral drug pipeline advancements.
Beyond corporate roles, Dr. Frost has contributed to prestigious institutions, including the Board of Regents of the Smithsonian Institution, the Board of Trustees of the University of Miami, and the Scripps Research Institutes. His board service extends to entities like Non-Invasive Monitoring Systems and Grove Bank & Trust, reflecting a broad impact in healthcare, finance, and governance.
View full insider profile →
Discussion